SOURCE-LINKED STUDY SUMMARY
Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man.
Abstract summarizedQuality not appraised
- What was studied
- Two small sleep-laboratory cohorts tested bedtime MK-677 effects on measured sleep stages in healthy young and older adults.
- Who / model studied
- Participants were eight young adults aged 18–30 years and six older adults aged 65–71 years.
- Studied dose & schedule
- Young adults received oral MK-677 5 mg, 25 mg, or placebo at bedtime for seven days each. Older adults received 2 mg then 25 mg for 14 days each, with washouts.
- What the study found
- In young adults, 25 mg increased stage IV sleep about 50% and REM sleep over 20% versus placebo. In older adults, MK-677 was associated with nearly 50% more REM sleep and shorter REM latency. Adverse events were not reported in the abstract.
- Limitations & context
- The cohorts totaled 14 people and exposure lasted one or two weeks. The older-adult sequence lacked a reported placebo comparison, and sleep-stage changes do not establish durable clinical benefit.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1159/000127249